How does Shanggong Medical Letter move from AI image to service platform?

Jingxin, the CEO of the technology company focusing on fundus screening and chronic disease management, told Yiou Da Health that it has completed 40 million yuan of Series A financing recently. The investors include Haida Investment, Zhuhai Yisheng Technology and Guangfa Dry and.

Based on the diabetes community, from technology products to service platforms

From the outside world, this company that uses AI technology to drive medical services is a bit "slow" compared to the AI+ medical companies that frantically financed last year. However, Ji Xin said that the Shanggong Medical Letter does not stop at the AI medical products that are screened by sugar nets.

Like many players who first entered the “AI+Medical” circle, initially, the AI ​​products of Shanggong Medical Letters also experienced a series of “evolutions” from scientific research accumulation to clinical landing, from single disease to expansion. It is worth noting that the Shanggong Medical Letter is always aimed at diabetes and cardiovascular and cerebrovascular risks brought about by eye health.

At the beginning of its establishment in 2014, Shanggong Medical Letters from the use of machine learning technology intelligent screening for the application of "sugar network disease" in hospital internal medicine, launched "Huayan Sugar Network" AI fundus screening products, based on the big data cloud service platform AutoEye, Interpretation of the disease's quantitative indicators and progression of the disease to screen for sugar net disease, other eye diseases, and cardiovascular and cerebrovascular diseases.

"'There is no disease in the work, the disease is already cured, the next work is cured.' The logic of prevention has existed since ancient times, which coincides with the "healthy China" strategy currently being implemented by the country." Ji Xin said. "The fundamental difference between the company and the AI+ medical imaging startup in the industry is that the Shanggong Medical Letter has to be a service platform in the segmentation field since its establishment, covering all aspects from screening, diagnosis, treatment to prognosis.

The first step is to have "tools". Technology is a front-end product, such as "Gift Eye Candy Net." However, Ji Xinjue is not satisfied with the role of Shanggong Medical Letter in a “technical company”, so he goes to the second step and expands the service radius. This is also the positioning logic of Shanggong Medical Letter from technical products to service platforms.

On the landing, in addition to the expansion of AI screening product diseases (glaucoma, cataract, etc.), Shanggong Medical Letter also provides online service channels for hospitals, doctors and patients to provide online diversion referrals, and ultimately with the fundus big data analysis platform. Integrate and gradually build a full management service that integrates data management, information sharing, and doctor-patient communication.

According to reports, the service platform is designed for national early-stage disease screening and treatment, for hospitals with precise diversion patients, and for ophthalmologists to stay in the most suitable positions. On the other hand, it also contributes to the national “grading diagnosis and treatment” strategy. Advancement.

In addition, on the government side, Shanggong Medical Letter became the long-term strategic partner of China Microcirculation Society in 2016, and became the exclusive technology provider of “China Sugar Net Screening Project”. At present, Jiangsu Province is cooperating with the government to launch a pilot project for diabetes management services. On the enterprise side, Shanggong Medical Letter is piloting its AI medical products and management services in more than 10 medical examination institutions in China.

AI+ medical "second half"

Has AI+ Medical been welcoming the second half? Maybe it is. In December 2017, the Ministry of Industry and Information Technology issued the "Three-Year Action Plan for Promoting the Development of a New Generation of Artificial Intelligence Industry (2018-2020)", focusing on the promotion of cross-border integration of "Artificial Intelligence +" in the fields of medical imaging-assisted diagnostic systems. Realize the extension and breakthrough of the industrial value chain.

In addition, according to statistics, from 2013 to 2017, domestic AI medical sector startups have raised more than 240, and this data continues to grow.

As far as the market environment is concerned, after experiencing the “killing” of technology and money in the previous two years, each player has wisely put his eyes on “landing”. Ji Xin believes that at this stage, the biggest test for the track enterprises is the ability to land and integrate.

In the early days, many hospitals were still in a “trial” state for this technology due to the immaturity of the product. With the continuous accumulation of effective data and the gradual issuance of the second-class medical device approval by the State Food and Drug Administration, the auxiliary diagnostic products represented by AI sugar mesh screening products can be called “mature” development, and the hospital side This degree of cooperation and willingness to pay will also increase.

In the field of medical imaging, entrepreneurs emphasize "robustness", which is the universality and click-through rate of AI medical products. "In order to achieve the robustness of the product, we spent nearly a year." Ji Xin told Yiou Health. As of this financing, Shanggong Medical Letter has served nearly 400 hospitals with fundus cameras nationwide, and the AI ​​sugar mesh screening products of these hospitals only use the medical doctors.

In terms of integration, control and rehabilitation are critical to the chronic disease of diabetes. Ji Xin still insists that whether it is early screening of diabetes or disease management, it still needs to go to the medical institutions, and direct to C is not a wise road. In addition to early screening and full-process management with the hospital, Shanggong Medical Letter also cooperates with multinational pharmaceutical company Merck to provide drug delivery services.

After this round of financing, Shanggong Medical Letter will continue to use funds for product polishing, landing promotion and construction of external cooperation platforms. “Everyone in the industry likes to say 'tracks', but I think that when there is no way at the beginning, everyone will help to get out of the road and become the track.” Ji Xin said that he is following this “slow” industry. The tide is walking, but in his heart, the Shanggong Medical Letter is always doing something "unique".

Torch Shaped Wafer Ice Cream Cone

Torch Shaped Wafer Ice Cream Cone,Wafer Products In The Shape Of Torch,Wafer Cone Filled With Soft Ice,Flat Mouth Conical Wafer Products

Tianjin Yongkang Food Co., Ltd , https://www.yongkangfood.com